Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Clinical trial NCT01284192 · COMPLETED

Trial details

NCT number: NCT01284192
Sponsor: Astellas Pharma Inc
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Malignancies Positive for Anaplastic Lymphoma Kinase Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS Solid Tumor B-Cell Lymphoma

Start date: 2010-12-01
Primary completion: 2014-02-01
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.